SANUWAVE Health, Inc. (OTC:SNWV) Financial Performance Analysis

Company Overview - SANUWAVE Health, Inc. focuses on developing and commercializing non-invasive, biological response-activating devices for the healthcare sector, primarily targeting chronic conditions and wound healing [1] Financial Performance - SANUWAVE has a Return on Invested Capital (ROIC) of 54.33%, significantly higher than its Weighted Average Cost of Capital (WACC) of 15.85%, resulting in a ROIC to WACC ratio of 3.43, indicating substantial returns on invested capital [2][6] - TSS, Inc. has the second-highest ROIC to WACC ratio of 2.02 among peers, with a ROIC of 23.21% and a WACC of 11.51%, reflecting efficient capital utilization [3][6] - Pressure BioSciences, Inc. has a ROIC of 42.55% but a high WACC of 67.83%, leading to a ROIC to WACC ratio of 0.63, indicating less effective capital utilization [4] - Rafarma Pharmaceuticals, Inc. shows a ROIC of 3.03% and a WACC of 5.49%, resulting in a ROIC to WACC ratio of 0.55, suggesting inefficient capital utilization [4] - GulfSlope Energy, Inc. has a concerning ROIC of -1932.28% against a WACC of 5.71%, resulting in a negative ratio of -338.65, indicating it is not covering its cost of capital [5] - Aspen Group, Inc. also presents a negative ROIC of -4.51% and a WACC of 17.88%, leading to a ratio of -0.25, which is a red flag for potential investors [5]